PCVX
Vaxcyte Inc.
$43.03
-$2.26(-4.98%)
57
Overall
60
Value
66
Tech
47
Quality
Market Cap
$5.48B
Volume
1.40M
52W Range
$27.66 - $116.00
Target Price
$98.00
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | |||||||
| Operating Expenses | $89.6M | $103.7M | $232.3M | $468.0M | $569.5M | ||
| Research & Development | $73.6M | $78.4M | $169.5M | $332.3M | $476.6M | ||
| Research Expense | $73.6M | $78.4M | $169.5M | $332.3M | $476.6M | ||
| Selling, General & Administrative | $16.0M | $25.3M | $39.8M | $60.7M | $92.9M | ||
| General & Administrative Expenses | $16.0M | $25.3M | $39.8M | $60.7M | $92.9M | ||
| Depreciation & Amortization | $1.4M | $1.8M | $2.6M | $3.2M | $7.0M | ||
| Depreciation & Amortization | $1.4M | $1.8M | -- | -- | -- | ||
| Other Operating Expenses | $-287.0K | $-461.0K | -- | -- | -- | ||
| OPERATING INCOME | |||||||
| Operating income | $-89.6M | $-103.7M | $-232.3M | $-468.0M | $-569.5M | ||
| EBITDA | $-87.8M | $-96.6M | $-214.3M | $-392.1M | $-448.1M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $7.0K | $7.0K | $2.0K | -- | -- | ||
| Intinc | $244.0K | $344.0K | $8.4M | $62.9M | $110.0M | ||
| Net Non-Operating Interest Income/Expense | $237.0K | $337.0K | $8.4M | $62.9M | $110.0M | ||
| Gain on Sale of Securities | -- | $2.0K | -- | -- | -- | ||
| Other Income/Expense | $-2.5M | $-1.6M | $-24.5M | $-2.9M | $4.4M | ||
| Other Special Charges | $2.5M | $1.6M | -- | $2.9M | $-4.4M | ||
| SPECIAL ITEMS | |||||||
| Special Income Charges | $-267.0K | -- | $-213.0K | -- | -- | ||
| Impairment of Capital Assets | $267.0K | -- | -- | -- | -- | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-89.2M | $-100.1M | $-223.5M | $-402.3M | $-463.9M | ||
| Pre-Tax Income | $-89.2M | $-100.1M | $-223.5M | $-327.3M | $-463.9M | ||
| NET INCOME | |||||||
| Net Income | $-89.2M | $-100.1M | $-223.5M | $-402.3M | $-463.9M | ||
| Net Income (Continuing Operations) | $-89.2M | $-100.1M | $-223.5M | $-402.3M | $-463.9M | ||
| Net Income (Discontinued Operations) | $-89.2M | $-100.1M | $-223.5M | $-402.3M | $-463.9M | ||
| Net Income (Common Stockholders) | $-89.2M | $-100.1M | $-223.5M | $-402.3M | $-463.9M | ||
| TOTALS | |||||||
| Total Expenses | $89.6M | $103.7M | $232.3M | $468.0M | $569.5M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $29.5M | $51.9M | $64.9M | $97.2M | $122.0M | ||
| Average Shares Outstanding (Diluted) | $29.5M | -- | $64.9M | $97.2M | $122.0M | ||
| Shares Outstanding | $51.3M | $56.3M | $80.0M | $108.4M | $128.8M | ||
| Basic EPS | $-3.02 | $-1.93 | $-3.44 | $-4.14 | $-3.8 | ||
| Basic EPS (Continuing Operations) | $-3.02 | $-1.93 | $-3.44 | $-4.14 | $-3.8 | ||
| Diluted EPS | $-3.02 | $-1.93 | $-3.44 | $-4.14 | $-3.8 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-3.44 | $-4.14 | $-3.8 | ||
| OTHER METRICS | |||||||
| Gain On Sale Of P P E | -- | -- | $-44.0K | -- | -- | ||
| Other Gand A | $16.0M | $25.3M | $39.8M | $60.7M | $92.9M | ||
| Rent And Landing Fees | $700.0K | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PCVX | $43.03 | -5.0% | 1.40M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |